Covered recipient · General Payments record
MOHAMMED EL-DALLAL
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
General Payments · PY2022–2024
$1,605.23
- Reported across 29 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $970.50 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $353.03 | 9 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $193.14 | 1 |
| BOSTON SCIENTIFIC CORPORATION | $131.36 | 1 |
| Phathom Pharmaceuticals, Inc. | $124.97 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $122.15 | 1 |
| GENZYME CORPORATION | $26.37 | 1 |
| QOL Medical, LLC | $19.48 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $27.32 | 01/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103682545 | CMS |
| ABBVIE INC. | $124.61 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103682547 | CMS |
| ABBVIE INC. | $3.44 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103682549 | CMS |
| ABBVIE INC. | $23.14 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103682551 | CMS |
| ABBVIE INC. | $2.93 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103682553 | CMS |
| ABBVIE INC. | $18.42 | 03/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103682555 | CMS |
| ABBVIE INC. | $123.68 | 11/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103682557 | CMS |
| ABBVIE INC. | $7.07 | 12/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103682559 | CMS |
| ABBVIE INC. | $22.42 | 12/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103682561 | CMS |
| Boston Scientific Corporation | $131.36 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1092350403 | CMS |
| GENZYME CORPORATION | $26.37 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139790229 | CMS |
| Phathom Pharmaceuticals, Inc. | $124.97 | 08/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151058183 | CMS |
| QOL Medical, LLC | $19.48 | 08/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147711948 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $193.14 | 04/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153699289 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $122.15 | 07/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137538673 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.